Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Merger & Restructuring

Zydus Lifesciences Merger & Restructuring

Zydus Lifesciences incorporated a new wholly owned subsidiary, Zara Merger SUB Inc., in the United States on April 24, 2026. The entity is part of an internal group restructuring within the pharmaceutical industry. The subsidiary has not yet commenced business operations and currently reports nil turnover.

Source

NSE filing, NSE: ZYDUSLIFE. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Zydus Lifesciences Ltd: key numbers

Share price
₹1,184.40
Market cap
₹1,19,178 Cr
Revenue (annual)
₹27,148 Cr
Net profit (annual)
₹5,040 Cr
P/E (TTM)
26.4×Sector 46.1×
Promoter holding
75.01%+0.00% QoQ
FII holding
7.05%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Zydus Lifesciences Ltd

All →
18:27 IST NSE
Partnership

Zydus Lifesciences Partnership

Zydus Lifesciences' division Zylidac Bio partnered with Prolific Machines to scale their next-generation biologics manufacturing platform for GMP production.

11:09 IST NSE
Regulatory Approval

Zydus Lifesciences Regulatory Approval

Zydus Lifesciences received USFDA approval for its Estradiol-Levonorgestrel Transdermal System ANDA, designated as a CGT. The product is eligible for 180-day exclusivity upon first commercial marketing.

Other merger & restructuring announcements

All →